Metabolic surgery mitigates early kidney injury in obese youth with diabetes by suppressing mTORC1/JAK-STAT signaling.
Summary
In paired kidney biopsies from obese youth with T2D before and 12 months after VSG, renal hyperfiltration, kidney volume, mesangial matrix, and microalbuminuria improved. scRNAseq revealed suppressed glycolysis/gluconeogenesis/TCA programs with AMPK/FOXO3 upregulation, decreased pS6K (reduced mTORC1), and diminished PT JAK-STAT signaling corroborated by proteomics.
Key Findings
- Post-VSG, renal hyperfiltration, kidney volume, mesangial matrix area, and microalbuminuria decreased alongside metabolic improvements.
- scRNAseq in proximal tubule and thick ascending limb showed repression of glycolysis/gluconeogenesis/TCA genes with AMPK and FOXO3 upregulation.
- Reduced pS6K indicated attenuated mTORC1 activity; PT JAK-STAT activation was diminished and correlated with lower circulating ligands in Teen-LABS proteomics.
Clinical Implications
Supports kidney risk reduction after VSG and highlights mTORC1/JAK-STAT as candidate targets for pharmacologic kidney protection in obesity/T2D; informs biomarker development for patient selection and monitoring.
Why It Matters
This mechanistic human study directly connects bariatric surgery to renal molecular reprogramming (mTORC1 and JAK-STAT) in youth with T2D, revealing therapeutic nodes that may be targeted non-surgically.
Limitations
- Small primary sample size (n=5) and single-center design limit generalizability
- Non-randomized pre-post design susceptible to time-varying confounders
Future Directions
Validate renal molecular signatures and test pharmacologic modulators of mTORC1/JAK-STAT to emulate surgical benefits without surgery.
Study Information
- Study Type
- Cohort
- Research Domain
- Pathophysiology
- Evidence Level
- III - Small prospective paired pre-post cohort with mechanistic single-cell and proteomic validation
- Study Design
- OTHER